Invented by Matthew Bernett, Seung Chu, Gregory Moore, John Desjarlais, Xencor Inc
The market for bispecific antibodies that bind to CD38 and CD3 is rapidly growing, thanks to their potential in treating various types of cancer. CD38 is a cell surface protein that is highly expressed on multiple myeloma cells, while CD3 is a protein found on T cells. By targeting both CD38 and CD3 simultaneously, bispecific antibodies can effectively redirect T cells to attack cancer cells, leading to improved therapeutic outcomes.
One of the key drivers of the market for bispecific antibodies targeting CD38 and CD3 is the increasing prevalence of multiple myeloma, a type of blood cancer that affects plasma cells. According to the American Cancer Society, an estimated 34,920 new cases of multiple myeloma will be diagnosed in the United States in 2021 alone. This growing patient population creates a significant demand for innovative therapies, such as bispecific antibodies, that can provide better treatment options.
The success of bispecific antibodies targeting CD38 and CD3 can be attributed to their unique mechanism of action. These antibodies work by binding to CD38 on cancer cells, which triggers the activation of nearby T cells expressing CD3. This activation leads to the formation of an immunological synapse between the T cell and the cancer cell, ultimately resulting in the destruction of the cancer cell by the T cell.
Several pharmaceutical companies have recognized the potential of bispecific antibodies targeting CD38 and CD3 and have invested heavily in their development. One of the most notable examples is the FDA-approved bispecific antibody, Blenrep (belantamab mafodotin), developed by GlaxoSmithKline. Blenrep targets CD38 on multiple myeloma cells and CD3 on T cells, and it has shown promising results in clinical trials, leading to its approval for the treatment of relapsed or refractory multiple myeloma.
The market for bispecific antibodies targeting CD38 and CD3 is also fueled by the increasing interest in immunotherapies. Immunotherapy has revolutionized cancer treatment by harnessing the power of the immune system to fight cancer. Bispecific antibodies that bind to CD38 and CD3 represent a novel approach within the field of immunotherapy, providing a more targeted and potent treatment option for patients.
Furthermore, the market for bispecific antibodies targeting CD38 and CD3 is expected to expand as more research uncovers the potential of these therapies in other types of cancer. While multiple myeloma is the primary focus, ongoing studies are exploring the use of these bispecific antibodies in solid tumors and other hematological malignancies. If successful, this expansion of indications could significantly increase the market size and provide additional treatment options for patients with different types of cancer.
In conclusion, the market for bispecific antibodies that bind to CD38 and CD3 is experiencing rapid growth due to their potential in treating multiple myeloma and other types of cancer. With the increasing prevalence of multiple myeloma and the success of FDA-approved therapies like Blenrep, pharmaceutical companies are investing in the development of these innovative therapies. As research continues to uncover the full potential of bispecific antibodies targeting CD38 and CD3, the market is expected to expand further, providing new treatment options for patients and improving outcomes in the fight against cancer.
The Xencor Inc invention works as follows
The invention provides novel heterodimeric protein including heterodimeric antibody.
Background for Bispecific antibodies that bind to CD38 andCD3